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Objectives: To assess the hypothesis that an adjunctive therapy with methylprednisolone and unfractionated
heparin (UFH) or with methylprednisolone and low molecular weight heparin (LMWH) are more effective in
reducing any-cause mortality in critically-ill ventilated patients with pneumonia from SARS-CoV-2 infection
compared to LMWH alone.
Trial design: The study is designed as a multi-centre, interventional, parallel group, superiority, randomized,
investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be
randomly assigned to one of the three treatment groups in a ratio 1:1:1.
Participants: Inpatients will be recruited from 8 Italian Academic and non-Academic Intensive Care Units
Inclusion Criteria (all required): 1. Positive SARS-CoV-2 diagnostic (on pharyngeal swab of deep airways material)
2. Positive pressure ventilation (either non-invasive or invasive) from > 24 hours
3. Invasive mechanical ventilation from < 96 hours
4. PaO2/FiO2 ratio lower than 150 mmHg
5. D-dimer level > 6 times the upper limit of normal reference range
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6. C-reactive Protein > 6-fold upper the limit of normal reference range
Exclusion Criteria: 1. Age < 18 years
2. On-going treatment with anticoagulant drugs
3. Platelet count < 100.000/mm3
4. History of heparin-induced thrombocytopenia
5. Allergy to sodium enoxaparin or other LMWH, UFH or methylprednisolone
6. Active bleeding or on-going clinical condition deemed at high risk of bleeding contraindicating anticoagulant
treatment
7. Recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery
8. Chronic assumption or oral corticosteroids
9. Pregnancy or breastfeeding or positive pregnancy test. In childbearing age women, before inclusion, a pregnancy
test will be performed if not available
10. Clinical decision to withhold life-sustaining treatment or “too sick to benefit”
11. Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days
given their pre-existing medical condition)
12. Lack or withdrawal of informed consent
Intervention and comparator: • LMWH group: patients in this group will be administered enoxaparin at standard
prophylactic dosage.
• LMWH + steroid group: patients in this group will receive enoxaparin at standard prophylactic dosage and
methylprednisolone.
• UFH + steroid group: patients in this group will receive UFH at therapeutic dosages and methylprednisolone.
UFH will be administered intravenously in UFH + steroid group at therapeutic doses. The infusion will be started at
an infusion rate of 18 UI/kg/hour and then modified to obtain aPTT Ratio in between the range of 1.5-2.0. aPTT will
be periodically checked at intervals no longer than 12 hours. The treatment with UFH will be administered up to
ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with
LMWH in the destination ward up to clinical judgement of the attending physician.
Enoxaparin will be administered in both LMWH group and LMWH + steroid group at standard prophylactic dose (i.e.,
4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be
administered subcutaneously once a day up to ICU discharge. After ICU discharge it may be continued or
interrupted in the destination ward up to clinical judgement of the attending physician.
Methylprednisolone will be administered in both LMWH + steroid group and UHF + steroid group intravenously with
an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times
daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
Main Outcomes: Primary Efficacy Endpoint:
All-cause mortality at day 28
Secondary Efficacy Endpoints:
- Ventilation free days (VFDs) at day 28, defined as the total number of days that patient is alive and free of
ventilation (either invasive or non-invasive) between randomization and day 28 (censored at hospital discharge).
- Need of rescue administration of high-dose steroids or immune-modulatory drugs;
- Occurrence of switch from non-invasive to invasive mechanical ventilation during ICU stay;
- Delay from start of non-invasive ventilation to switch to invasive ventilation;
- All-cause mortality at ICU discharge and hospital discharge;
- ICU free days (IFDs) at day 28, defined as the total number of days between ICU discharge and day 28.
- Occurrence of new infections from randomization to day 28; including infections by Candida, Aspergillus,
Adenovirus, Herpes Virus e Cytomegalovirus
- Occurrence of new organ dysfunction and grade of dysfunction during ICU stay.
- Objectively confirmed venous thromboembolism, stroke or myocardial infarction;
Safety endpoints:
- Occurrence of major bleeding, defined as transfusion of 2 or more units of packed red blood cells in a day,
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bleeding that occurs in at least one of the following critical sites [intracranial, intra-spinal, intraocular (within the
corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular
with compartment syndrome, or retroperitoneal], bleeding that necessitates surgical intervention and bleeding that
is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death);
- Occurrence of clinically relevant non-major bleeding, defined ad acute clinically overt bleeding that does not
meet the criteria for major and consists of any bleeding compromising hemodynamic; spontaneous hematoma
larger than 25 cm2, intramuscular hematoma documented by ultrasonography, haematuria that was macroscopic
and was spontaneous or lasted for more than 24 hours after invasive procedures; haemoptysis, hematemesis or
spontaneous rectal bleeding requiring endoscopy or other medical intervention or any other bleeding requiring
temporary cessation of a study drug.
Randomization: A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by 3
factors: Centre, BMI (<30/≥30) and Age (<75/≥75). Central randomisation will be performed using a secure, web-
based, randomisation system with an allocation ratio of 1:1:1. The allocation sequence will be generated by the
study statistician using computer generated random numbers.
Blinding (masking): Participants to the study will be blinded to group assignment.
Numbers to be randomised (sample size): The target sample size is based on the hypothesis that the combined
use of UHF and steroid versus the LMWH group will significantly reduce the risk of death at day 28. The overall
sample size in this study is expected to be 210 with a randomization 1:1:1 and seventy patients in each group.
Assuming an alpha of 2.5% (two tailed) and mortality rate in LMWH group of 50%, as indicated from initial studies
of ICU patients, the study will have an 80% power to detect at least a 25 % absolute reduction in the risk of death
between: a) LMHW + steroid group and LMWH group or b) UHF + steroid group and LMWH group. The study has
not been sized to assess the difference between LMHW + steroid group and UHF + steroid group, therefore the
results obtained from this comparison will need to be interpreted with caution and will need further adequately
sized studies confirm the effect.
On the basis of a conservative estimation, that 8 participating sites admit an average of 3 eligible patients per
month per centre (24 patients/month). Assuming that 80 % of eligible patients are enrolled, recruitment of 210
participants will be completed in approximately 10 months.
Trial Status: Protocol version 1.1 of April 26th, 2020.
Recruitment start (expected): September 1st, 2020
Recruitment finish (expected): June 30th, 2021
Trial registration: EudraCT number 2020-001921-30, registered on April 15th, 2020
AIFA approval on May 4th, 2020
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
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